Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Gilead Sciences (GILD)
NASDAQ:GILD
Gilead Sciences (GILD) Stock Price & Analysis
12,621 Followers
GILD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$61.32 - $85.92
Previous Close$68.64
Volume4.85M
Average Volume (3M)7.74M
Market Cap
$85.52B
Enterprise Value$109.24B
Total Cash (Recent Filing)$1.18B
Total Debt (Recent Filing)$24.99B
Price to Earnings (P/E)191.4
Beta0.51
Next Earnings
Aug 08, 2024EPS Estimate
$1.59Last Dividend Ex-Date
Jun 14, 2024Dividend Yield4.4%
Share Statistics
EPS (TTM)0.36
Shares Outstanding1,245,853,209
10 Day Avg. Volume11,454,879
30 Day Avg. Volume7,742,526
Standard Deviation0.07
R-Squared0.02
Alpha0.00366
Financial Highlights & Ratios
Price to Book (P/B)-7.38
Price to Sales (P/S)12.37
Price to Cash Flow (P/CF)10.20
P/FCF Ratio10.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.04
Enterprise Value/Gross Profit5.30
Enterprise Value/Ebitda10.41
Forecast
1Y Price Target
$77.82Price Target Upside13.77% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering25
Gilead Sciences News
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyLenacapavir demonstrated 100% efficacy and zero infections in cisgender women, reflecting its strong potential as a preferred PrEP treatment.
Innovation And DevelopmentGS-4571, a novel oral GLP-1 small molecule, has shown promising weight loss results in non-human primates and mice, indicating potential efficacy and adding to Gilead's innovative pipeline.
Market PotentialThe US PrEP market is currently only about one-third penetrated, with potential to increase to 50-60% overall with long-acting treatments like lenacapavir.
Bears Say
OncologyTrodelvy failed to demonstrate a statistically significant improvement in overall survival compared to chemotherapy, missing the study’s primary endpoint.
Pipeline PerformanceThe rash of negative Trodelvy updates made for a challenging past week for Trodelvy's outlook and, in turn, for Gilead's oncology ambitions.
Regulatory ChallengesTrodelvy will likely lose its FDA-labeled indication for metastatic urothelial carcinoma (mUC), or bladder cancer, following the disappointing topline overall survival miss for TROPiCS-04.
---
Ownership Overview
0.91% Insiders
30.95% Mutual Funds
26.81% Other Institutional Investors
41.33% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
ProductionRisks related to the company’s ability to manufacture goods and services
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GILD FAQ
What was Gilead Sciences’s price range in the past 12 months?
Gilead Sciences lowest stock price was $61.32 and its highest was $85.92 in the past 12 months.
What is Gilead Sciences’s market cap?
Currently, no data Available
When is Gilead Sciences’s upcoming earnings report date?
Gilead Sciences’s upcoming earnings report date is Aug 08, 2024 which is in 37 days.
How were Gilead Sciences’s earnings last quarter?
Gilead Sciences released its earnings results on Apr 25, 2024. The company reported -$1.32 earnings per share for the quarter, beating the consensus estimate of -$1.493 by $0.173.
Is Gilead Sciences overvalued?
According to Wall Street analysts Gilead Sciences’s price is currently Undervalued.
Does Gilead Sciences pay dividends?
Gilead Sciences pays a Quarterly dividend of $0.77 which represents an annual dividend yield of 4.4%. See more information on Gilead Sciences dividends here
What is Gilead Sciences’s EPS estimate?
Gilead Sciences’s EPS estimate is $1.59.
How many shares outstanding does Gilead Sciences have?
Gilead Sciences has 1,245,853,100 shares outstanding.
What happened to Gilead Sciences’s price movement after its last earnings report?
Gilead Sciences reported an EPS of -$1.32 in its last earnings report, beating expectations of -$1.493. Following the earnings report the stock price went up 0.233%.
Which hedge fund is a major shareholder of Gilead Sciences?
Among the largest hedge funds holding Gilead Sciences’s share is Dodge & Cox. It holds Gilead Sciences’s shares valued at 2B.
---
Gilead Sciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$77.82 (13.77% Upside)
$77.82 (13.77% Upside)
Blogger Sentiment
Bullish
GILD Sentiment 93%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 392.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 6.8%
Last 30 Days ▲ 6.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-7.19%
12-Months-Change
Fundamentals
Return on Equity
2.51%
Trailing 12-Months
Asset Growth
-9.02%
Trailing 12-Months
Company Description
Gilead Sciences
Founded in 1987, California-based Gilead Sciences, Inc. is a biopharmaceutical company, which focuses on the research, development, and commercialization of antiviral drugs used in the treatment of diseases like human immunodeficiency virus (HIV), hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi. It offers its products under brands including Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi.
---
GILD Company Deck
---
GILD Earnings Call
Q1 2024
0:00 / 0:00
---
GILD Revenue Breakdown
67.03% HIV
8.05% Veklury
6.89% Cell Therapy
6.52% HCV
11.51% Other
---
GILD Stock 12 Month Forecast
Average Price Target
$77.82
▲(13.77% Upside)
Technical Analysis
Best Analysts Covering GILD
1 Year
1 Year Success Rate
34/60 ratings generated profit
1 Year Average Return
+5.93%
assigned a buy rating 13 days ago
Copying Salim Syed's trades and holding each position for 1 Year would result in 56.67% of your transactions generating a profit, with an average return of +5.93% per trade.
---